Catalog Number UNKENTERPRISE |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Thromboembolism (2654); Ischemia Stroke (4418)
|
Event Date 03/01/2023 |
Event Type
Injury
|
Manufacturer Narrative
|
Manufacturer¿s ref.No: (b)(4).This complaint is from a literature source and the following citation was reviewed: li z, xuan j, fang x, zhao x, zhang b, wu d, lai n, liu j, zhang z, yuan j, qin f.Comparison of enterprise stent 2 with 1 in assisting coiling of ruptured aneurysms: a real-world study.J comp eff res.2022 aug;11(12):879-887.Doi: 10.2217/cer-2022-0005.Epub 2022 jun 23.Pmid: 35734978.Section d.4: the product catalog and lot numbers are not available / not reported.The unique identifier (udi) and expiration date of the device is not known.Section e.1: the initial reporter phone is not available / reported.Section h.4: the device manufacture date is not known as the device lot number is not available / not reported.Since the event is life threatening and it might result in permanent impairment of a body function or permanent damage to a body structure; or it could require medical or surgical intervention to prevent permanent impairment of a body function or permanent damage to a body structure, it is to be considered serious.The event is reportable to the us fda.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by cerenovus, or its employees that the report constitutes an admission that the product, cerenovus, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.The manufacturer will submit a supplemental report if new facts arise which materially alter information submitted in a previous mdr report.Additional information will be submitted within 30 days of receipt.
|
|
Event Description
|
This complaint is from a literature source and the following citation was reviewed: li z, xuan j, fang x, zhao x, zhang b, wu d, lai n, liu j, zhang z, yuan j, qin f.Comparison of enterprise stent 2 with 1 in assisting coiling of ruptured aneurysms: a real-world study.J comp eff res.2022 aug;11(12):879-887.Doi: 10.2217/cer-2022-0005.Epub 2022 jun 23.Pmid: 35734978.Purpose/objective/methods:objective: to assess the safety and efficacy of sac using neuroform atlas for treating ria compared with coiling alone by performing a propensity score matching analysis.Methods: ria treated with coiling alone and sac between january 2017 and may 2021 were retrospectively reviewed.Demographics, periprocedural complication rates, angiographic outcomes, and clinical outcomes of the sac using neuroform atlas group and the coiling-alone group were analyzed with 1:1 propensity score matching.Lot, model and catalog number are not available, but the suspected cerenovus device possibly associated with reported adverse events: enterprise stent.Cerenovus devices that were used in this study: n/a.Non-cerenovus devices that were also used in this study: neuroform atlas stent (stryker), lvis stent (microvention).Exact product quantities cannot be determined as a patients can experience more than one adverse event.Adverse event(s) and provided interventions (table 3) possibly associated with unidentified enterprise stent: qty 1 in-stent thrombosis treated with tirofiban.Qty 1 cerebral infarct.
|
|
Search Alerts/Recalls
|
|